Citius Pharma
Manufacturing · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
11 Commerce Dr Fl 1, Cranford, New Jerse...Phone Number
(908) 967-6677Website
www.citiuspharma.comRevenue
<$5 MillionStock Symbol
CTXRIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
1
1
1
About Citius Pharma
Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. Citius Pharmaceuticals was founded in 2007, and is headquartered in Cranford, New Jersey.Explore more
Citius Pharma Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Citius Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Citius Pharma had a recent Job posting/layoffs
Check if Citius Pharma has recently received funding, and reach out quickly before it becomes old news!
Check out if Citius Pharma is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Citius Pharma
Earning: See what the market has to say on Citius Pharma recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Citius Pharma launches new products
Funding: Get notified immidiatlly once Citius Pharma has new funding data
Citius Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Citius Pharma
Find 2 more new buyers
Compare Similar Companies to Citius Pharma
Compare insights from companies similar to Citius Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Citius Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Citius Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Citius Pharma.
Citius Pharma financials insights
Gather financial insights about Citius Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
2021
Share Placement
$20M
Citius Pharma Tech Stack
A closer look at the technologies used by Citius Pharma
Most Recent Scoops
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Person-Based
Earnings, Finance, Investor Relations
Person-Based
Project
Partnership, Business Development, Pharmaceuticals
Citius Pharma News & Media
Citius Pharmaceuticals (CTXR) starts LYMPHIR sales but faces heavy loss and going concern risk
Citius Pharmaceuticals booked $5.6M LYMPHIR revenue but lost $37.5M, burned $14.3M operating cash, recorded large CMO termination charges and warned of going concern risk beyond November 2026 despite new equity and loan financings.Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
$5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR® Citius Pharma raised $5 million in a registered direct offering; Citius Oncology secured up to $36.5 million in debt and equity financing Advanced patient access with payer coverage near 100% of...Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
$5.6 million in net revenue for the first half of fiscal 2026 as LYMPHIR® launch progresses Up to $36.5 million in debt and equity capital secured Broad payer coverage established with no reimbursement denials 83% of target accounts on formulary or in review CRANFORD, N.J., May 15, 2026...Citius Pharmaceuticals (NASDAQ: CTXR) closes $5 million stock and warrant financing
Citius Pharmaceuticals completed a $5.0 million registered direct and private warrant offering, issuing 5,076,143 shares or pre-funded warrants plus 5,076,143 unregistered warrants to fund LYMPHIR and pipeline programs.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Citius Pharma
Sign Up For FreeTo access detailed company insights
Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. Citius Pharmaceuticals was founded in 2007, and is headquartered in Cranford, New Jerse... Read More
